Enhancing the protection of influenza virus vaccines with BECC TLR4 adjuvant in aged mice

被引:6
作者
Haupt, Robert [1 ,2 ,8 ]
Baracco, Lauren [1 ,2 ]
Harberts, Erin M. [3 ]
Loganathan, Madhumathi [4 ]
Kerstetter, Lucas J. [1 ]
Krammer, Florian [4 ,5 ,6 ]
Coughlan, Lynda [1 ,7 ]
Ernst, Robert K. [3 ]
Frieman, Matthew B. [1 ,2 ]
机构
[1] Univ Maryland, Sch Med, Dept Microbiol & Immunol, Baltimore, MD 21201 USA
[2] Univ Maryland, Ctr Pathogen Res, Sch Med, Baltimore, MD 21201 USA
[3] Univ Maryland, Sch Dent, Dept Microbial Pathogenesis, Baltimore, MD USA
[4] Icahn Sch Med, Dept Microbiol, New York, NY USA
[5] Icahn Sch Med Mt Sinai, Ctr Vaccine Res & Pandem Preparedness C VARPP, New York, NY USA
[6] Icahn Sch Med Mt Sinai, Dept Pathol Mol & Cell Based Med, New York, NY USA
[7] Univ Maryland, Ctr Vaccine Dev & Global Hlth CVD, Sch Med, Baltimore, MD 21201 USA
[8] USAMRIID, Mol Biol Div, Therapeut Discovery Branch, Ft Detrick, MD USA
关键词
FLUAD(R);
D O I
10.1038/s41598-023-27965-x
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Influenza A virus (IAV) is a leading cause of respiratory disease worldwide often resulting in severe morbidity and mortality. We have previously shown that the Bacterial Enzymatic Combinatorial Chemistry (BECC) adjuvants, BECC438 and BECC470, formulated with an influenza virus hemagglutinin (HA) protein vaccine, offer greater protection from influenza virus challenge in mouse respiratory models using adult mice than standard HA:adjuvant combinations. In this study, we determined that immunization with HA + BECC adjuvants also significantly broadened the epitopes targeted on HA as compared with other adjuvants, resulting in increased titers of antibodies directed against the highly conserved HA stalk domain. Importantly, we demonstrate that BECC470 combined with an influenza virus HA protein antigen in a prime-only immunization regimen was able to achieve complete protection from challenge in a similar to 12-month-old mouse aged model. Together, this demonstrates the heightened protection provided by the BECC470 adjuvant in an influenza virus vaccine model and shows the enhanced immune response, as compared to other adjuvants elicited by the formulation of HA with BECC470.
引用
收藏
页数:12
相关论文
共 34 条
[1]   A single-shot adenoviral vaccine provides hemagglutinin stalk-mediated protection against heterosubtypic influenza challenge in mice [J].
Bliss, Carly M. ;
Freyn, Alec W. ;
Caniels, Tom G. ;
Leyva-Grado, Victor H. ;
Nachbagauer, Raffael ;
Sun, Weina ;
Tan, Gene S. ;
Gillespie, Virginia L. ;
McMahon, Meagan ;
Krammer, Florian ;
Hill, Adrian V. S. ;
Palese, Peter ;
Coughlan, Lynda .
MOLECULAR THERAPY, 2022, 30 (05) :2024-2047
[2]  
Chung ER, 2022, MMWR-MORBID MORTAL W, V71, P365, DOI 10.15585/mmwr.mm7110a1
[3]   Vaccine Adjuvants: Putting Innate Immunity to Work [J].
Coffman, Robert L. ;
Sher, Alan ;
Seder, Robert A. .
IMMUNITY, 2010, 33 (04) :492-503
[4]   Overcoming Barriers in the Path to a Universal Influenza Virus Vaccine [J].
Coughlan, Lynda ;
Palese, Peter .
CELL HOST & MICROBE, 2018, 24 (01) :18-24
[5]   MF59-adjuvanted influenza vaccine (FLUAD®) elicits higher immune responses than a non-adjuvanted influenza vaccine (Fluzone®): A randomized, multicenter, Phase III pediatric trial in Mexico [J].
Cruz-Valdez, Aurelio ;
Valdez-Zapata, Gabriel ;
Patel, Sanjay S. ;
Castelli, Flavia V. ;
Garcia, Marcia G. ;
Jansen, Wim T. ;
Arora, Ashwani Kumar ;
Heijnen, Esther .
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2018, 14 (02) :386-395
[6]   Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection [J].
DiLillo, David J. ;
Palese, Peter ;
Wilson, Patrick C. ;
Ravetch, Jeffrey V. .
JOURNAL OF CLINICAL INVESTIGATION, 2016, 126 (02) :605-610
[7]   Broadly neutralizing hemagglutinin stalk-specific antibodies require FcγR interactions for protection against influenza virus in vivo [J].
DiLillo, David J. ;
Tan, Gene S. ;
Palese, Peter ;
Ravetch, Jeffrey V. .
NATURE MEDICINE, 2014, 20 (02) :143-151
[8]   Efficacy and safety of a quadrivalent influenza vaccine in children aged 6-35 months: A global, multiseasonal, controlled, randomized Phase III study [J].
Esposito, Susanna ;
Nauta, Jos ;
Lapini, Giulia ;
Montomoli, Emanuele ;
van de Witte, Serge .
VACCINE, 2022, 40 (18) :2626-2634
[9]   Antibody response to influenza vaccination in the elderly: A quantitative review [J].
Goodwin, K ;
Viboud, C ;
Simonsen, L .
VACCINE, 2006, 24 (08) :1159-1169
[10]   A lipid A-based TLR4 mimetic effectively adjuvants a Yersinia pestis rF-V1 subunit vaccine in a murine challenge model [J].
Gregg, Kelsey A. ;
Harberts, Erin ;
Gardner, Francesca M. ;
Pelletier, Mark R. ;
Cayatte, Corinne ;
Yu, Li ;
McCarthy, Michael P. ;
Marshall, Jason D. ;
Ernst, Robert K. .
VACCINE, 2018, 36 (28) :4023-4031